


IDENTIFICATION OF NOVEL SUSCEPTIBILITY GENE(S) FOR RENAL CELL CARCINOMA

Principal Investigators: W. Marston Linehan, MD
Bert Zbar, MD
SCC Coordinator: Heather Symecko MA.
NIH Coordinator: Lindsay Middleton, RN, CGC

Accrual Start Date (Projected): 1/2004
Accrual End Date (Projected):
Study End Date (Projected):
Participating Groups: CGN, NIH

Goal: Develop a repository of DNA samples from patients with “sporadic” renal cell carcinoma for use in studies to identify novel susceptibility gene(s) for renal cell carcinoma

Schema



IDENTIFICATION OF NOVEL SUSCEPTIBILITY GENE(S) FOR RENAL CELL CARCINOMA

Study Objectives:

- 1) Develop a resource of DNA samples from patients with “sporadic” renal cell carcinoma for use in studies to identify novel susceptibility gene(s) for renal cell carcinoma;
- 2) Employ a genome-wide approach to identify regions that contain susceptibility loci for renal cell carcinoma by using standard methods of segregation analysis, aggregation analysis and case- control association analysis; and
- 3) Compare regions showing positive evidence of association to regions mapped by LOH in renal cancer tumors.

Eligibility Criteria:

Inclusion Criteria for Cases

- Individuals with biopsy proven renal cell carcinoma
- Individuals diagnosed with renal cell carcinoma within two years of enrollment
- ≥ 18 years-old
- No multiple primary cancers

Inclusion Criteria for Controls

- ≥ 18 years-old
- No previous or current cancer diagnosis, other than non-melanoma skin cancer
- Non-biological relative to enrolled case
- Matches to a case in study on:
 - Geographic Area: same geographic area as case
 - Age: must be within 5 years of matched case age
 - Gender
 - Ethnicity: (not matching on Asian sub-ethnicity)

Participating Centers:

Site
Georgetown University
MD Anderson
Baylor
UT Southwest
Johns Hopkins University
Duke University
University of California – Irvine
Northwest CGN

Data Management and Specimen Collection:

Staff at Massachusetts General Hospital (MGH) provides database support through administration of TrialDB and scannable forms development. Specimens will be collected and processed by NIH.